[
  {
    "ts": null,
    "headline": "2025 Dividend Kings: Strong Run Continues",
    "summary": "Discover the top-performing Dividend Kings of 2025, outperforming the S&P 500 by 4.57%. Click here to explore more promising picks.",
    "url": "https://finnhub.io/api/news?id=a74c64a6727c91e36bd84f432d4b5654822919d70d02376d5d8c3b53f8bfe7c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742561991,
      "headline": "2025 Dividend Kings: Strong Run Continues",
      "id": 133307231,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178712905/image_2178712905.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover the top-performing Dividend Kings of 2025, outperforming the S&P 500 by 4.57%. Click here to explore more promising picks.",
      "url": "https://finnhub.io/api/news?id=a74c64a6727c91e36bd84f432d4b5654822919d70d02376d5d8c3b53f8bfe7c7"
    }
  },
  {
    "ts": null,
    "headline": "J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease",
    "summary": "FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.",
    "url": "https://finnhub.io/api/news?id=3bc107610bea84887c31038912ce021fe33f80792063c32a0c1887b3ae30560d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742560080,
      "headline": "J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease",
      "id": 133324555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "FDA approves J&J's Tremfya for its fourth indication and the second IBD condition.",
      "url": "https://finnhub.io/api/news?id=3bc107610bea84887c31038912ce021fe33f80792063c32a0c1887b3ae30560d"
    }
  },
  {
    "ts": null,
    "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
    "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
    "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742541707,
      "headline": "Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy",
      "id": 133297533,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1444529209/image_1444529209.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects for long-term investment.",
      "url": "https://finnhub.io/api/news?id=2012cfbaa433b0233c82b4e2650cde3928bdf1857ae5c68c2d115d433190debb"
    }
  }
]